4 stories mentioning SHE:002332Updated 3d ago
Every FINWIRES story that references SHE:002332, newest first.
Zhejiang Xianju Pharmaceutical (SHE:002332) said 30%-owned associate Xianju Hongju Microcredit plans to exit the microcredit industry and cut registered capital by 104.5 million yuan proportionally.Upon completion, Hongju Microcredit's registered capital will drop to 500,000 yuan, according to a Friday filing with the Shenzhen bourse.Shares of the pharmaceutical company closed 2% lower Friday.
The U.S. Food and Drug Administration accepted Zhejiang Xianju Pharmaceutical's (SHE:002332) abbreviated new drug application for progesterone vaginal tablets, according to a Wednesday filing with the Shenzhen bourse.The tablets help support embryo implantation and early pregnancy by supporting luteal function, according to the filing.
Zhejiang Xianju Pharmaceutical (SHE:002332) said the 1ml:50mg specification for progesterone injection passed China's generic drug consistency evaluation.The injection is indicated for menstrual disorders, luteal deficiency, threatened and habitual abortion, premenstrual tension syndrome, and assisted reproductive therapy, according to a Wednesday filing with the Shenzhen bourse.The pharmaceutical company already holds approvals for 1ml:10mg and 1ml:20mg specifications.Shares of Zhejiang Xianju Pharmaceutical were down 2% Wednesday.
China's drug regulator approved Zhejiang Xianju Pharmaceutical's (SHE:002332) registration of its betahistine mesylate tablets, according to a Saturday filing with the Shenzhen Stock Exchange.The tablets are indicated for vertigo associated with Meniere's disease, the filing said.
